PT3071595T - Anticorpo anti calicreína-2 humanizado - Google Patents

Anticorpo anti calicreína-2 humanizado

Info

Publication number
PT3071595T
PT3071595T PT14814696T PT14814696T PT3071595T PT 3071595 T PT3071595 T PT 3071595T PT 14814696 T PT14814696 T PT 14814696T PT 14814696 T PT14814696 T PT 14814696T PT 3071595 T PT3071595 T PT 3071595T
Authority
PT
Portugal
Prior art keywords
calicrein
antibody
humanized anti
humanized
Prior art date
Application number
PT14814696T
Other languages
English (en)
Portuguese (pt)
Inventor
Strand Sven-Erik
SJÖSTRÖM Kjell
Oskar Vilhelmsson Timmermand Pär
Thuy Tran Amanda
Juhani Lamminmäki Urpo
Original Assignee
Fredax Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1320408.6A external-priority patent/GB2520353A/en
Priority claimed from GB201401973A external-priority patent/GB201401973D0/en
Application filed by Fredax Ab filed Critical Fredax Ab
Publication of PT3071595T publication Critical patent/PT3071595T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
PT14814696T 2013-11-19 2014-11-19 Anticorpo anti calicreína-2 humanizado PT3071595T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1320408.6A GB2520353A (en) 2013-11-19 2013-11-19 Antibody polypeptides and uses thereof
GB201401973A GB201401973D0 (en) 2014-02-05 2014-02-05 Antibody polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
PT3071595T true PT3071595T (pt) 2019-06-11

Family

ID=52114029

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14814696T PT3071595T (pt) 2013-11-19 2014-11-19 Anticorpo anti calicreína-2 humanizado

Country Status (24)

Country Link
US (3) US10100125B2 (https=)
EP (2) EP3553088B1 (https=)
JP (4) JP6599859B2 (https=)
KR (3) KR102442738B1 (https=)
CN (2) CN112898431B (https=)
AU (3) AU2014351611B2 (https=)
BR (1) BR112016011025B1 (https=)
CA (1) CA2930493A1 (https=)
CY (1) CY1121900T1 (https=)
DK (2) DK3071595T3 (https=)
ES (1) ES2728515T3 (https=)
FI (1) FI3553088T3 (https=)
HR (1) HRP20191095T1 (https=)
HU (1) HUE043875T2 (https=)
IL (5) IL297678B2 (https=)
LT (1) LT3071595T (https=)
MX (2) MX383543B (https=)
PL (1) PL3071595T3 (https=)
PT (1) PT3071595T (https=)
RS (1) RS58831B1 (https=)
RU (1) RU2687163C1 (https=)
SI (1) SI3071595T1 (https=)
SM (1) SMT201900338T1 (https=)
WO (1) WO2015075445A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013061083A2 (en) 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
MY193914A (en) 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
SMT201900338T1 (it) 2013-11-19 2019-07-11 Fredax Ab Anticopri anti-callicreina-2 umanizzato
DK3123381T3 (da) 2014-03-28 2023-11-27 Opko Diagnostics Llc Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
WO2017087826A1 (en) * 2015-11-18 2017-05-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
EP4649966A3 (en) 2016-12-01 2026-02-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
KR102317805B1 (ko) * 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
SG11202000073XA (en) 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
BR112021022237A2 (pt) 2019-05-10 2022-03-29 Janssen Biotech Inc Queladores macrocíclicos e métodos de uso dos mesmos
AU2020322221A1 (en) 2019-07-26 2022-03-24 Janssen Biotech, Inc. Anti-hK2 chimeric antigen receptor (CAR)
BR112022001368A2 (pt) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
EP4182353A1 (en) 2020-07-17 2023-05-24 Janssen Biotech, Inc. Anti-idiotypic antibodies against anti-klk2 antibodies
UY39510A (es) * 2020-11-10 2022-05-31 Janssen Biotech Inc Compuestos macrocíclicos y métodos para usarlos
CN112608365B (zh) * 2020-12-22 2021-07-30 吉林省特医食品生物科技有限公司 一种减轻体重的发酵型小分子肽及其制备方法和应用
CN114790245A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途
JP2024503924A (ja) * 2021-01-27 2024-01-29 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用
WO2022165130A1 (en) * 2021-01-28 2022-08-04 Astria Therapeutics, Inc. Plasma kallikrein antibodies and uses thereof
US20230011134A1 (en) * 2021-05-27 2023-01-12 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
CA3240194A1 (en) 2021-11-09 2023-05-19 Edward Cleator Macrocyclic compounds and methods of making the same
JP2024543046A (ja) 2021-11-09 2024-11-19 ヤンセン バイオテツク，インコーポレーテツド 大環状化合物及びその診断上の使用
EP4469095A1 (en) 2022-01-26 2024-12-04 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2025244971A1 (en) 2024-05-20 2025-11-27 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CN1238013A (zh) 1996-11-14 1999-12-08 梅奥医学教育及研究基金会 转移性前列腺癌的检测方法
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
WO2001012218A1 (en) 1999-08-16 2001-02-22 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20040219163A1 (en) * 2001-10-03 2004-11-04 Frelinger John G. Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP2347767A3 (en) 2003-01-31 2013-06-12 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
CN101094869A (zh) * 2004-08-03 2007-12-26 戴埃克斯有限公司 Hk1结合蛋白
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US8663600B2 (en) * 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
ES2560868T3 (es) * 2006-12-22 2016-02-23 Phadia Ab Alérgeno de calicreína de próstata novedoso
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
WO2013061083A2 (en) * 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
SMT201900338T1 (it) 2013-11-19 2019-07-11 Fredax Ab Anticopri anti-callicreina-2 umanizzato
WO2023278463A1 (en) 2021-06-29 2023-01-05 Volastra Therapeutics, Inc. Anti-enpp1 antibodies and uses thereof

Also Published As

Publication number Publication date
US20220064333A1 (en) 2022-03-03
IL278493A (en) 2022-12-01
AU2014351611A1 (en) 2016-06-30
AU2014351611B2 (en) 2020-04-23
KR20160096621A (ko) 2016-08-16
FI3553088T3 (fi) 2026-04-21
EP3071595A1 (en) 2016-09-28
JP2016540503A (ja) 2016-12-28
EP3071595B1 (en) 2019-03-20
ES2728515T3 (es) 2019-10-25
HUE043875T2 (hu) 2019-09-30
RS58831B1 (sr) 2019-07-31
JP7051777B2 (ja) 2022-04-11
IL311788A (en) 2024-05-01
HRP20191095T1 (hr) 2019-09-20
BR112016011025A2 (pt) 2017-12-05
BR112016011025A8 (pt) 2018-01-30
KR102442738B1 (ko) 2022-09-15
IL323633A (en) 2025-11-01
RU2687163C1 (ru) 2019-05-07
CA2930493A1 (en) 2015-05-28
IL297678A (en) 2022-12-01
JP7592654B2 (ja) 2024-12-02
JP2025019101A (ja) 2025-02-06
IL245617B (en) 2021-02-28
DK3071595T3 (da) 2019-07-01
IL311788B1 (en) 2025-11-01
LT3071595T (lt) 2019-05-10
CN112898431B (zh) 2024-05-28
IL278493B2 (en) 2023-04-01
AU2023222879A1 (en) 2023-09-14
JP2020022470A (ja) 2020-02-13
BR112016011025B1 (pt) 2024-01-23
IL297678B2 (en) 2024-09-01
CY1121900T1 (el) 2020-10-14
AU2020207775A1 (en) 2020-08-06
KR102574537B1 (ko) 2023-09-06
RU2016124229A (ru) 2017-12-25
EP3553088A1 (en) 2019-10-16
US10100125B2 (en) 2018-10-16
JP6599859B2 (ja) 2019-10-30
US11230609B2 (en) 2022-01-25
US20160369009A1 (en) 2016-12-22
IL245617A0 (en) 2016-06-30
WO2015075445A1 (en) 2015-05-28
EP3553088B1 (en) 2026-03-04
US20190169312A1 (en) 2019-06-06
CN105980404B (zh) 2021-01-12
CN105980404A (zh) 2016-09-28
SMT201900338T1 (it) 2019-07-11
PL3071595T3 (pl) 2019-09-30
IL297678B1 (en) 2024-05-01
IL311788B2 (en) 2026-03-01
JP2022062048A (ja) 2022-04-19
AU2020207775B2 (en) 2023-06-15
KR102894975B1 (ko) 2025-12-04
DK3553088T3 (da) 2026-04-27
US12404343B2 (en) 2025-09-02
MX2021007006A (es) 2021-09-08
KR20230132599A (ko) 2023-09-15
MX383543B (es) 2025-03-14
MX2016006561A (es) 2016-12-12
SI3071595T1 (sl) 2019-08-30
KR20220020406A (ko) 2022-02-18
CN112898431A (zh) 2021-06-04

Similar Documents

Publication Publication Date Title
CY2023021I1 (el) Αντισωματα που δεσμευουν την il-23
PT3071595T (pt) Anticorpo anti calicreína-2 humanizado
DK3736291T5 (da) Anti-FCRH5-antistoffer
ME03675B (me) Humanizovana ili himerna anтi-cd3 antiтela
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
IL246287B (en) Fabs-in-tandem immunoglobulin and uses thereof
LT3049441T (lt) Anti-pdl1 antikūnų kompozicija
BR112014024769A2 (pt) anticorpo humanizado tau
EP3083682C0 (en) DOUBLE SPECIFICITY ANTIBODIES
KR20180085002A (ko) 인간화된 항-cll-1 항체
PT3088419T (pt) Conjugado de anticorpo anti-trop2-fármaco
EP3070168C0 (en) ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
SMT201800541T1 (it) Dispositivo di chiusura
IL243311A0 (en) Novel antibody frameworks
DK3068800T3 (da) FcRn-specifikke antistoffer
PL3088421T3 (pl) Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej
IL240753B (en) Methods for purifying antibodies
ME03094B (me) Protutijela protiv kemokina pan-elr+ схс
GB201300706D0 (en) Antibody
DK3065774T3 (da) Anti-CCL17-antistoffer
DK3047163T3 (da) Lukkeelement
HRP20190085T1 (hr) Anti-cd52 protutijela
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
PL2970503T3 (pl) Przeciwciała monoklonalne przeciw-(+) --metamfetaminie
TH1401006962A (th) แอนติ-ทรานสกลูตามิเนส 2 แอนติบอดี